Summary Inhibition of clonogenic potential by the glycinamideribonucleosyl transformylase inhibitor 5,10-dideazatetrahydrofolic acid (DDATHF, Lometrexol) 
Summary Inhibition of clonogenic potential by the glycinamideribonucleosyl transformylase inhibitor 5,10-dideazatetrahydrofolic acid (DDATHF, Lometrexol) was evaluated in vitro in a human ovarian carcinoma cell line, SW626. Drug-induced inhibition of clonogenic potential is a function of the dose and time of exposure and is independent of the formation of DNA single-strand breaks or de novo synthesis of protein. Simultaneous treatment with 1OOiLM hypoxanthine completely prevented the inhibition of clonogenic potential caused by 0.5 ILM DDATHF. DDATHF blocked cells in the early-middle S-phases of the cell cycle, and there was a correponding marked reduction in the rate of DNA synthesis after drug withdrawal. The cytotoxic potential of DDATHF was modulated by the folic acid concentration present in the medium. In a medium containing 0.22 gM folic acid, DDATHF cytotoxicity was at least 100 times that in a regular medium containing 2.221LM folic acid, levels which, however, are about 100 times those found in human plasma. DDATHF cytotoxicity differed moderately when folic acid concentrations varied between 0.22 and 011M, suggesting that folic acid does not necessarily antagonise DDATHF anti-tumour activity. Folinic acid at a concentration as low as 0.1IJM can completely rescue cells when given simultaneously with 0.5 gAM DDATHF. When folinic acid was given 24 h after DDATHF, a reversal of cytotoxicity was observed at 0.5 and I gAM, but to a much lesser extent than simultaneous treatment. When folinic acid was added after 48 or 72 h of DDATHF washout, even at a high concentration and for a long time, no reduction in DDATHF cytotoxicity was found. In conclusion, the study highlights the modulation of DDATHF cytotoxicity by folic acid or by folinic acid and provides further rationale for in vivo clinical investigation with these combinations.
5,10-Dideazatetrahydrofolic acid (DDATHF, Lometrexol) is an anti-cancer agent under early clinical investigation in Europe and in the USA. It is the first clinically investigated antifolate whose mode of action is related to the inhibition of glycinamideribonucleosyl (GAR) transformylase, a key enzyme in the de novo synthesis of purines (Moran et al., 1985; Beardsley et al., 1989; Taylor et al., 1989; Baldwin et al., 1991) . Many aspects of the cellular pharmacology of DDATHF have already been investigated in detail. DDATHF appears to be a good substrate for membrane folate-binding proteins (mFBP) (Kane et al., 1988; Westerhof et al., 1991) , which probably act as a relevant carrier for its intracellular transport. The intracellular transport can also be mediated by the reduced folate carrier (Pizzorno et al., 1993) . Once in the cell, DDATHF is efficiently biotransformed to polyglutamated metabolites, which are much more potent inhibitors of GAR transformylase than the monoglutamated parent compound (Pizzorno et al., 1991a).
What is not yet known is the mechanism of cytotoxicity consequent to GAR transformylase inhibition. Like other antifolates (Lorico et al., 1988 ) DDATHF could cause DNA damage, which will eventually result in cell death, but this hypothesis requires experimental verification.
During phase I clinical studies DDATHF showed severe and unexpected haematological and gastrointestinal toxicity in some patients (Muggia et al., 1990; Sessa et al., 1990; Ray et al., 1992) . Two approaches are currently under clinical investigation to reduce the risk of toxicity: (i) the concomitant administration of folic acid and (ii) the use of folinic acid as an antidote. Both approaches are based on findings in mice, but the mechanism by which folic and folinic acid counteract DDATHF-induced toxicity is not yet clear Grindey et al., 1992) .
The aim of this study was to investigate whether and how DDATHF affects the normal cell cycle distribution and DNA integrity of tumour cells exposed to cytotoxic concentrations of the drug and to obtain information on the influence of folic and folinic acid on the drug cytotoxicity.
Materials and methods
Cells and culture conditions The SW626 human ovarian carcinoma cell line was used (Sen et al., 1990) . For all these experiments cells were grown as monolayers in RPMI-1640 medium supplemented with 10% dialysed fetal bovine serum (FBS) (cut-off point 3,500 Da). In order to assess the role of folic acid in the medium, cells were grown in. progressively lower folate-containing media. Cell viability and clonogenicity The effect of the drug on the cells was evaluated by a standard clonogenic assay . One thousand cells were plated in 3 ml of medium in 60 mm-diameter Petri dishes. Cell viability was checked using erythrosin B. The colonies were allowed to develop for 14 days. Plating efficiency of the untreated, exponentially growing control cells was between 85 and 90%. The colonies were stained with 1% crystal violet solution in 20% ethanol and the number of colonies and mean clone area were measured using the IBAS 20 (Zeiss, Germany) image analysis system. A background correction was done and the smallest size of the control cell colony was taken as the minimum for setting the cut-off point.
Flow cytometric analysis of cell cycle phase distribution and BrdU uptake Monoparametric conventional cell cycle analysis using propidium iodide (a specific fluorescent dye for DNA) was carried out on control and treated cells at different times of drug treatment and after drug washout using a FACStar plus (Becton Dickinson) instrument coupled to a Hewlett Packard computer system . Cell cycle phase percentages were calculated by the method of Krishan and Frei (1976) .
For biparametric BrdU/DNA analysis (Sen et al., 1990) , 30 JLM BrdU was added to the cells for 30 min at different times during DDATHF treatment and after drug washout, and fixed with 70% ethanol at 4°C. The cells were washed with phosphate-buffered saline (PBS) and DNA was denatured with 3 M hydrochloric acid for 30 min at room temperature. The denaturation was stopped by addition of 0.1 M sodium borate (pH 8.5) in excess and the cells were centrifuged. The cells were incubated for 15 min with a solution of 0.5% Tween 20 in PBS and 1% normal goat serum. BrdU uptake was detected after 1 h incubation with 100 gd of antiBrdU monoclonal antibody diluted 1:10 in 0.5% Tween 20 in PBS then another 1 h incubation with 100 gld of fluorescinconjugated goat anti-mouse IgG diluted 1:50 in 5% Tween 20 in PBS. After washing with PBS, the cells were resuspended in a solution of 5Lgml-' propidium iodide in PBS and 10,000 U of ribonuclease for at least 2 h in the dark.
Flow cytometric immunofluorescence analysis on MO V18 MOV18 expression was detected in SW626 cells growing in RPMI with 2.2 lJM or without folic acid after 1 h incubation with 100 gl of MOV18 antibody diluted 10 tg ml-' in PBS with 0.3% bovine serum albumin (BSA). After washing with PBS, the cells were incubated for 1 h with 100 gIl of fluorescein-conjugated anti-mouse IgG developed in goats diluted 1:50 in 5% Tween 20 in PBS.
Alkaline elution
Exponentially growing cells were incubated with '4C-labelled thymidine for 24 h. The radioactive label was removed and the cells were chased for a further 24 h. DNA single-strand breaks were assessed by alkaline elution methods slightly modified previously (Kohn et al., 1981) . DNA breaks were assessed in parallel in samples X-irradiated with 300 rad as positive controls.
Results
The clonogenic inhibitory effect of DDATHF is shown in The drug has been reported to inhibit GAR transformylase, a major regulatory enzyme in de novo purine biosynthesis. This causes a lack of inosinate, one of the main precursors of purines. Addition of 100 ItM hypoxanthine simultaneously with 0.5 jiM DDATHF reversed the inhibitory effect of the drug-induced clonogenicity (Figure 3) tion of hypoxanthine (100 JAM) the colonies were smaller than controls, suggesting that adding hypoxanthine to the medium is sufficient for colony formation but is not enough to restore the normal growth rate of SW626 in the 2 weeks after treatment (data not shown).
The drug-induced cell cycle perturbations and the level of DNA synthesis are shown in Figure 4a . Monoparametric DNA analysis (shown in the upper panels marked lA-lIA), indicated that 0.5 JAM DDATHF treatment for 24 h decreased the proportion of cells in G2/M phases after an accumulation in S-middle phase of the cell cycle, up to 72 h of recovery in drug-free medium. DNA synthesis, as evaluated by uptake of 30 JAM BrdU at specific points during treatment and recovery times, was established by biparametric BrdU/DNA flow cytometric analysis as shown in Figure 4(1B-1l B) . Between 4 h (6B) and 24 h (9B) recovery time in drug-free medium, DNA synthesis (BrdU level) progressively dropped to maximum inhibition at 24 h recovery (9B). Between 48 and 72 h recovery, the DNA synthesis rate became similar to exponentially growing untreated control cells (1 B). This effect is graphically represented in Figure 4b .
The mechanism by which DDATHF-induced inhibition of purine synthesis caused its cytotoxicity is unknown. Since the inhibition of DNA synthesis appears transient and is restored completely 48 h after DDATHF washout, the cytotoxicity may not be directly related to the inhibition of DNA synthesis.
The inhibition of thymidine synthesis by MTX or CB3717 was associated with the formation of DNA breaks, and the inhibitor of protein synthesis, cycloheximide, prevented these DNA breaks, also reducing the cytotoxicity of the drug (Lorico et al., 1988) . Therefore, it was of interest to verify whether another antifolate that blocks purine biosynthesis without affecting thymidine synthesis also caused DNA damage and if cycloheximide could modify these DNA breaks and drug-induced cytotoxicity. As shown in Figure 5 , DDATHF-induced DNA breaks were not detectable even after 48 h drug exposure, whereas under similar experimental conditions MTX caused a significant number of DNA breaks. Cycloheximide, 2.5 and 5 JLM (inhibiting protein synthesis by 50% and 90% respectively in 10 min, data not shown), did not reverse the action of the drug after simultaneous application for 24 h. As shown-in Figure 6 , cycloheximide at the highest dose tested, 5 JAM for 24 h, did not affect clonogenicity, indicating that inhibition of de novo protein synthesis is not involved in drug-induced cytotoxicity.
In order to assess how the folic acid content of the medium modified the clonogenic inhibitory effect of the drug, we performed different experiments using cells conditioned to grow in RPMI-1640 medium supplemented with 10% dialysed FBS, without or with different concentrations of folic acid. Figure 7 shows that the expression of mFBP assessed by using MOV18 antibody increased significantly in SW626 cells growing in the absence of folic acid. As shown in Figure  8 added simultaneously with the drug or immediately after drug washout completely reversed the cytotoxic activity. However, when folinic acid was added after 48 h or 72 h, DDATHF still had cytotoxic activity similar to when it was used alone. A concentration of folinic acid as low as 0.1 M was sufficient to rescue the cytotoxicity of DDATHF when given simultaneously. When folinic acid was given 24 h after DDATHF a reversal of cytotoxicity was obtained at 0.5 and 1 tLM, but to a much lesser extent. As shown in Figure 10 folinic acid effect reached a plateau at 1 riM. In order to assess the minimum time necessary for folinic 100 n * 100 1000 DDATHF (nM) When cells growing in folic acid-free medium were tested, 5 nM DDATHF completely inhibited their clonogenic potential. Co-administration of folinic acid in vivo completely reversed the drug-induced systemic toxic manifestations in experimental animals . To All these experiments strongly suggest that during the late post-treatment periods a short or long pulse of folinic acid is equally ineffective in reducing the cytotoxic potential of DDATHF.
Discussion
The results presented confirm that the mode of action of the antifolate DDATHF is distinct from other antifolates . DDATHF cytotoxicity has been related to the drug's ability to inhibit purine biosynthesis. However, the mechanism of cytotoxicity has still to be fully elucidated. In SW626 cells exposed to DDATHF the inhibition of DNA synthesis, consequent to the inhibition of de novo synthesis of purines, only becomes evident after a few hours and does not last long. This transient inhibition of DNA synthesis slows the progression of cells towards S-phase, but does not explain the cytotoxicity.
For other antifolates such as methotrexate (MTX), it has been proposed that cytotoxicity is due to the formation of DNA breaks, presumably caused by uracil misincorporation into DNA and/or activation of endonucleolytic enzymes (Li & Kaminskas, 1984; Lorico et al., 1988) . Since MTX inhibits both thymidine and purine synthesis, it has been suggested that the DNA fragmentation is triggered by the block of DNA synthesis. However, since the addition of thymidine abolishes the drug-induced DNA breakage and cytotoxicity (Lorico et al., 1988) , the effects may be due to thymidine deprivation. This is further supported by the fact that inhibitors of thymidylate synthase such as CB3717, which do not affect purine biosynthesis but only thymidine synthesis, also cause DNA breakage (Lorico et al., 1988) . The inhibitor of protein synthesis cycloheximide also inhibited MTX-or CB 3717-induced DNA breaks and cytotoxicity, suggesting that a neosynthesised protein was implicated in the mechanism of induction of DNA damage and cell death.
It was therefore of interest to study whether DDATHF, which to our knowledge is the only antifolate acting as a pure purine synthesis inhibitor, also induced DNA breakage and whether the inhibition of protein synthesis reduced the DNA damage and cytotoxicity. Our (Antony, 1992) , suggesting that differences in the expression of these proteins in neoplastic and normal tissues might be exploited to achieve drug selectivity towards some neoplasms (Jansen et al., 1989 . For example, in ovarian cancers mFBP, recognised by MOV18 and MOV19, have been shown to be overexpressed (Miotti et al., 1987) .
Preclinical animal studies have indicated that folic acid strongly reduces the toxicity of DDATHF without markedly inhibiting the anti-tumour activity Grindey et al., 1992) . The concentrations of folic acid may be important in the expression of mFBP and these effects may not be the same in tumour and normal tissues.
In order to investigate the importance of the folic acid concentration we have compared the cytotoxicity of DDATHF in medium containing 2.2 JAM folic acid and, after appropriate adaptation, lower concentrations. In folic acidfree medium the expression of mFBP, determined with the antibody MOV18 (Campbell et al., 1991) , was substantially greater in SW626 cells (Figure 7) , consistent with previous reports on the regulation of mFBP expression (Antony, 1992) . DDATHF sensitivity dramatically increased between 2.2 JAM and 0.22 JAM folic acid, with about two logs of difference in the IC50 values. We do not know what is the explanation for this increased sensitivity. The expression of mFBP was in fact only marginally increased when cells were grown in medium containing 0.22 AM folic acid compared with cells grown in medium containing 2.2 JAM folic acid (data not shown), thus suggesting that the change in drug sensitivity is not due to an induction of mFBP. The concentration of 2.2 JAM, normally present in the culture medium, is approximately 100 times the physiological values of folates in human plasma, which are mainly present in the form of 5-methyltetrahydrofolate. Even with a folic acid-rich diet this concentration cannot be achieved in vivo. At lower concentrations of folic acid, from 0 to 0.22 JAM, the differences in DDATHF cytotoxicity were smaller, indicating that in a physiological range the concentrations of folic acid only weakly influenced the inhibition of DDATHF cytotoxicity against these human ovarian cancer cells. When folic acid concentrations were below 0.22 JAM a marked cytotoxicity of DDATHF at concentrations of 5-10 nM was observed. These concentrations of DDATHF can be achieved and maintained in plasma of patients receiving tolerable DDATHF dose (D.R. Newell, personal communication). This may be in line with in vivo data showing that folic acid dramatically reduced the toxicity but only marginally affected the antitumour activity in mice (G.B. Grindey, personal communication) and provide a further experimental basis to investigate the combination of folic acid and DDATHF in clinical use.
Another potentially clinically relevant aspect is whether, and to what extent, the cytotoxic effects against tumour cells are antagonised by folinic acid, normally used as an antidote for high-dose MTX and under investigation as a modulator of DDATHF toxicity (Pizzorno et al., 1990; Sessa et al., 1992) .
In this study folinic acid completely antagonised DDATHF cytotoxicity when given simultaneously with DDATHF. The antagonism might be due to inhibition of intracellular transport, possibly by competition for the reduced folate carrier mechanism, or for mFBP, although folinic acid has been reported to have a low affinity for this high-affinity carrier. When the simultaneous treatment lasted only 2 h and DDATHF treatment was continued for a further 22 h after drug washout without any more folinic acid added, the antagonism persisted, possibly because the transport mechanism was saturated by folinic acid.
Alternatively, folinic acid may inhibit DDATHF polyglutamylation, which increases both intracellular drug retention and inhibitory potency on GAR transformylase. This is supported by previous findings in CCRF-CEM cells that folinic acid can inhibit polyglutamylation of DDATHF when given simultaneously with the drug. The same study, however, showed that if folinic acid was given 4 h after DDATHF there was no significant changes in the cellular content of the polyglutamated forms. Therefore although the antagonism observed on giving DDATHF and folinic acid simultane-ously may be partly due to inhibition of polyglutamylation, it appears unlikely that this mechanism explains the antagonism observed when folinic acid is given after 24 h exposure to DDATHF. In this case it appears more likely that the inhibition of GAR transformylase by DDATHF is abolished by competition of the coenzyme, 10-methyltetrahydrofolate, rapidly formed from folinic acid .
The reversal of the inhibition would result in rapid restoration of purine synthesis before the purine pools drop below a threshold level and for long enough for toxicity to occur. If the interval between DDATHF and folinic acid is longer (e.g. 48 or 72 h after DDATHF treatment) purine deprivation below that threshold will probably last long enough to trigger the mechanisms of cytotoxicity (still not known, as discussed above), and addition of folinic acid can no longer save the already damaged cells.
Folinic acid is currently used in some protocols to antago-nise the toxicity of DDATHF. The data of the present study suggest that there is the risk that folinic acid also blocks the anti-tumour effects. In our experimental conditions folinic acid given 24 h after DDATHF did not significantly reduce DDATHF's cytotoxic effect. Although it is difficult to extrapolate the data obtained on a cell line growing in vitro to the clinical situation, it seems reasonable to suggest that the interval between DDATHF and folinic acid must be of several days to avoid a reduction in anti-tumour activity, considering that human solid tumours grow much more slowly than SW626 cells.
